Sirtex Medical (ASX:SRX) has announced completion of patient recruitment into the RESIRT study investigating the use of SIRSpheres Y-90 resin microspheres for the treatment of primary Renal Cell Carcinoma (RCC), the most common type of kidney cancer.
The RESIRT study is an Australian-based, multi-centre, single arm, dose escalation study in patients with RCC that were not suitable for curative therapy by surgical re-section, ablation or other conventional techniques.
Dr David N. Cade, Sirtex’s Chief Medical Officer, said: “RESIRT represents our first clinical study investigating the use of SIR-Spheres microspheres outside of the liver. While partial or complete surgical removal of the kidney remains the standard treatment approach for primary kidney cancer, we believe SIR-Spheres microspheres may ultimately offer a minimally invasive treatment alternative for patients unable or unwilling to be treated surgically.”
According to SEER, there were estimated to be 61,560 new cases of kidney cancer in the US during 2015, representing 3.7 per cent of all cancer cases. Kidney cancer is the thirteenth most common cancer worldwide, with approximately 338,000 cases globally in 2012. RCC accounts for approximately 90 per cent of all new kidney cancers.
The company said initial results of the RESIRT study are anticipated to be available during the fourth quarter of calendar year 2016.